Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion's Cholesterol Drugs Receive Approval in Europe
02:43pm, Tuesday, 07'th Apr 2020
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Advisor Group Inc. Has $51,000 Stake in Esperion Therapeutics Inc (NASDAQ:ESPR)
08:50am, Tuesday, 07'th Apr 2020
Advisor Group Inc. decreased its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 33.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)
Needham Thinks Esperion's Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company's shares
Needham Thinks Esperion’s Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Esperion (
ESPR
–
Research Report
), with a price target of
$158.00
. The company’s shares closed last Monday at $32
Esperion announces European Commission approval of NUSTENDI tablet ESPR
11:38am, Monday, 06'th Apr 2020
Esperion announces European Commission approval of NUSTENDI tablet ESPR
Esperion announces European Commission approval of NILEMDO tablet ESPR
11:37am, Monday, 06'th Apr 2020
Esperion announces European Commission approval of NILEMDO tablet ESPR
Esperion's Nustendi OK'd in Europe
11:32am, Monday, 06'th Apr 2020
As expected, the European Commission has approved Esperion Therapeutics' (NASDAQ:ESPR) Nustendi (bempedoic acid and ezetimibe) for adults with primary hypercholesterolemia (heterozygous familial and n
Esperion (ESPR) announced today the European Commission approved the NUSTENDI™ (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hy
Esperion (ESPR) announced today the European Commission approved the NILEMDO™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine. NILEMDO is a first-
Reviewing Esperion Therapeutics (NASDAQ:ESPR) and AgeX Therapeutics (NASDAQ:AGE)
05:18am, Monday, 06'th Apr 2020
Esperion Therapeutics (NASDAQ:ESPR) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of
What You Need To Know About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analyst Downgrade Today
12:26pm, Sunday, 05'th Apr 2020
The analysts covering Esperion Therapeutics, Inc. (NASDAQ:ESPR) delivered a dose of negativity to shareholders today...
Revenue Downgrade: Here's What Analysts Forecast For Esperion Therapeutics, Inc. (NASDAQ:ESPR)
12:26pm, Sunday, 05'th Apr 2020
One thing we could say about the analysts on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - they aren't optimistic...
